Business Context and Reporting Period
Company: DaVita Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 17, 2010
Event: Entry into a Material Definitive Agreement with Amgen USA Inc.
Key Financial Metrics
This filing does not report specific revenue, profit, cash flow, margin, debt, or liquidity figures. The document focuses exclusively on the terms of a new supply agreement.
Material Changes Versus Prior Period
- Agreement Replacement: The new Dialysis Organization Agreement replaces the prior agreement effective January 1, 2008, which expired on December 31, 2010.
- Term: The new agreement commences January 1, 2011, and ends June 30, 2011.
- Pricing Structure: The agreement provides for discount pricing and rebates for Epoetin alfa (Epogen). The potential rebate levels are described as substantially similar to the expiring agreement.
- Conditions: Rebates are subject to qualification requirements based on process improvement targets, patient outcome targets, and data submission.
Guidance, Outlook, and Risks
- Supplier Relationship: Amgen remains the sole supplier of Epogen, a critical drug for DaVita's dialysis patients.
- Termination Rights: Either party may terminate the agreement before expiration with prior written notice.
- Regulatory Risk: The agreement allows for termination, modification, or renegotiation in the event of a change in law or regulation.
- Documentation: The full text of the agreement is expected to be filed as an exhibit to the Company's Annual Report on Form 10-K for the year ended December 31, 2010.
Investor Verification Checklist
- Verify the specific rebate qualification metrics (process improvement, patient outcomes) in the full agreement text.
- Confirm the impact of the six-month term (ending June 30, 2011) on future procurement planning.
- Monitor the upcoming Form 10-K filing for the full agreement exhibit and any related financial disclosures.
- Assess the risk of early termination given the "prior written notice" clause.